[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100622228":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":13,"centralContacts":18,"locations":7,"responsibleParty":27,"collaborators":7,"id":31,"slug":32,"hasResults":33,"nctId":34,"briefTitle":35,"officialTitle":36,"acronym":7,"eligibilityCriteria":37,"healthyVolunteers":33,"sex":38,"minAge":39,"maxAge":40,"enrollmentInfo":41,"targetDuration":7,"studyType":44,"phases":7,"briefSummary":45,"conditions":46,"keywords":7,"overallStatus":48,"whyStopped":7,"lastUpdateSubmitDate":49,"lastUpdatePostDateStruct":50,"startDateStruct":53,"completionDateStruct":55,"leadSponsor":57,"locationsCount":7},{"fullName":5,"class":6},"Sohag University","OTHER",null,[9],{"type":10,"name":11,"description":12,"armGroupLabels":7,"otherNames":7},"RADIATION","transthoracic echocardiography","Standard transthoracic echocardiography will be performed for all participants, measuring:\n\n* Left ventricular end-diastolic diameter (LVEDD)\n* Interventricular septal thickness (IVSD)\n* Posterior wall thickness (PWD)\n* Left ventricular mass (LVM)\n* Left ventricular mass index (LVMI = LVM\u002Fbody surface area)",[14],{"name":15,"affiliation":16,"role":17},"Amal Kh Ahmed, MD","Sohag university- faculty of medicine - internal medicine department","STUDY_CHAIR",[19,24],{"name":20,"role":21,"phone":22,"phoneExt":7,"email":23},"khaled M Mohamedein, MBCHB","CONTACT","+201507290373","drkhaledmmm1984@gmail.com",{"name":25,"role":21,"phone":26,"phoneExt":7,"email":7},"Marwa Z Elsayed, MD","+201007100970",{"type":28,"investigatorFullName":29,"investigatorTitle":30,"investigatorAffiliation":5,"oldNameTitle":7,"oldOrganization":7},"PRINCIPAL_INVESTIGATOR","Khaled Mohamed Mohamedin","resident of internal medicine","100622228","left-ventricular-hypertrophy-in-ckd-patients-100622228",false,"NCT07380893","Left Ventricular Hypertrophy in CKD Patients","Prevalence of Left Ventricular Hypertrophy (LVH) in CKD Patients and Effect of Erythropoietin Therapy","Inclusion Criteria:\n\n* Adults (≥18 years) diagnosed with CKD stages 3-5.\n* Stable clinical condition for ≥3 months.\n* Anemia (Hb \\\u003C10 g\u002FdL) for cohort phase.\n* Willingness to participate and provide informed consent.\n\nExclusion Criteria:\n\n* Valvular or ischemic heart disease.\n* Uncontrolled hypertension (BP \\>180\u002F110 mmHg).\n* Acute coronary syndrome or decompensated heart failure in the past 3 months.\n* Malignancy or active infection","ALL","18 Years","75 Years",{"count":42,"type":43},100,"ESTIMATED","OBSERVATIONAL","The goal of this observational study is to determine the prevalence of left ventricular hypertrophy among patients with chronic kidney disease at Sohag University Hospital and assess the effect of erythropoietin therapy on left ventricular mass and geometry in anemic CKD patients.\n\nThe main question it aims to answer is:\n\nDoes erythropoietin therapy mitigate or even reverse LVH and improve cardiac geometry ?",[47],"Left Ventricular Hypertrophy","NOT_YET_RECRUITING","2026-01-24",{"date":51,"type":52},"2026-02-02","ACTUAL",{"date":54,"type":43},"2026-01-15",{"date":56,"type":43},"2026-07-15",{"name":5,"class":6}]